NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/24/2026 15:26
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization891.51 mln
Float40.31 mln
Earnings Date07/30/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-5.52
Highly reliable
1-Year Forecast
45.25
Transformational upside
Relative Strength
98
/ 100
Top performer
Debt / Equity
0.00
Debt-free
ROE
-90.13
Deeply negative
Business Description
Founded in 2011 and based in Rockville, Maryland, Avalo Therapeutics is a U.S. biotech company working to bring new treatments to patients whose immune systems cause harmful inflammation. The company's most advanced drug candidate, AVTX-009, is currently being tested in a mid-stage clinical trial targeting a protein linked to inflammatory conditions. Previously operating under the name Cerecor Inc., the company rebranded as Avalo Therapeutics in August 2021.
